Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Unknown 1

Sponsor Class

OTHER 18INDUSTRY 2FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Acetylcysteine × Clear all
NCT04887194 2024-05-08

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

Mirati Therapeutics Inc.

Phase 1 Completed
40 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT02908750 2022-11-14

Study to Assess the Effect of Osimertinib (TAGRISSOâ„¢ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

AstraZeneca

Phase 1 Completed
24 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡